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Hypoxia-Inducible Factor 1 Alpha
Contributes to Cardiac Healing in Mesenchymal
Stem Cells-Mediated Cardiac Repair
Inmaculada Cerrada,1,2 Amparo Ruiz-Saurı´,3 Rube´n Carrero,1 Ce´sar Trigueros,4 Akaitz Dorronsoro,4
Jose Marı´a Sanchez-Puelles,5 Antonio Diez-Juan,6 Jose Anastasio Montero,1 and Pilar Sepu´lveda1
Mesenchymal stem cells (MSC) are effective in treating myocardial infarction (MI) and previous reports dem-
onstrated that hypoxia improves MSC self-renewal and therapeutics. Considering that hypoxia-inducible factor-
1 alpha (HIF-1a) is a master regulator of the adaptative response to hypoxia, we hypothesized that HIF-1a
overexpression in MSC could mimic some of the mechanisms triggered by hypoxia and increase their thera-
peutic potential without hypoxia stimulation. Transduction of MSC with HIF-1a lentivirus vectors (MSC-HIF)
resulted in increased cell adhesion and migration, and activation of target genes coding for paracrine factors.
When MSC-HIF were intramyocardially injected in infarcted nude rats, significant improvement was found
(after treatment of infarcted rats with MSC-HIF) in terms of cardiac function, angiogenesis, cardiomyocyte
proliferation, and reduction of fibrotic tissue with no induction of cardiac hypertrophy. This finding provides
evidences for a crucial role of HIF-1a on MSC biology and suggests the stabilization of HIF-1a as a novel strategy
for cellular therapies.
Introduction
Myocardial infarction (mi) is one of themain causes ofmortality andmorbidity in developed countries. Despite
progress in primary angioplasty mortality remain high [1,2].
Mesenchymal stem cells (MSC) have been used over the
past years as a novel therapy to treat MI and clinical studies
using MSC for cardiac tissue repair have been recently
completed (Prometheus; http://clinicaltrials.gov).
To improve MSC therapeutics, many strategies have been
conducted [3]. Preconditioning of MSC with hypoxia in-
duced the pro-survival Akt pathway and increased their
therapeutic potential in a model of hind limb ischemia [4].
Hypoxia-inducible transcription factors (HIFs) have been
identified as pivot molecular mediators enabling cell adap-
tation to hypoxia [5–10] and these molecules have been
correlated with cell survival [11–13]. Ischemic tissue elevates
levels of HIF-1a, which in turn regulate the expression of
nearly 200 genes affecting cellular responses to stress [13].
Genes regulated by HIF-1a include vascular endothelial
growth factor (VEGF), erythropoietin, angiopoietin, placen-
tal growth factor, and platelet-derived growth factor [14,15].
Culture of embryonic stem cells on fetal stromal cells over-
expressing HIF-1a improves their self-renewal and plur-
ipotency in comparison with maintenance on fibroblast-based
feeders [16]. The intracardiac injection of HIF-1a naked DNA
reduced the size of infarction and increased neovasculariza-
tion in the ischemic heart [17].
HIF-1a overexpression in MSC improved their survival and
therapeutic properties [18–20]. Considering the impact of HIF-
1a in the adaptative response to hypoxia we wanted to eval-
uate the impact of HIF activity on the therapeutic potential of
MSC during the treatment of ischemic cardiac diseases.
Materials and Methods
All procedures were approved by the Instituto de Salud
Carlos III and institutional ethical and animal care committees.
Cells, culture conditions, and lentiviral labeling
Human bone marrow MSC (n = 3; Inbiobank San Se-
bastian) were cultured following manufacturer’s instructions
and lentivirally transduced with pWIPI-green fluorescent
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protein (GFP) or pWIPI-HIF-GFP (http://addgene.org). To
label the cells, supernatants containing retroviral particles
obtained from the 293 packaging cell lines transduced with
pWIPI-GFP or pWIPI-HIF-GFP were filtered through
0.45 mm filter and added to MSC for 8 h, and then replaced by
fresh medium. Lentiviral transduction of MSC was per-
formed by incubating cells for 8 h with lentiviral particles at a
multiplicity of infection of 10 in MSC culture medium. Ti-
tration of lentiviral supernatants was performed in fresh
HEK293T by our Viral Vector Unit (http://inbiomed.org).
This procedure was repeated daily for 3 days. Transduction
efficiency in MSC was evaluated by flow cytometry. Per-
centage of infection was routinely higher than 90%.
Flow cytometry
Human MSC-GFP or MSC-HIF-GFP (passage 6–10) were
analyzed by flow cytometry (Coulter EPICS XL flow cytometer;
Beckman Coulter) to determine the percentage of GFP-positive
cells after lentiviral transduction. Data acquisition and analyses
were performed with Expo32 software (Beckman Coulter). The
cells were processed according to standard protocols.
Real-time polymerase chain reaction
Total RNA was prepared as described above. cDNA was
synthesized using M-MLV Reverse Trascriptase (Invitrogen;
http://qiagen.com). Real-time polymerase chain reaction
(qRT-PCR) was performed using LightCycler 480 SYBR Green
I Master (Roche Molecular Biochemical; http://roche.com)
with the LightCycler 480 (Roche) according to the manu-
facturer’s instructions. Quantitative PCR employed the fol-
lowing conditions: 95C at 10min, 40 cycles at 95C, 15 s;
58C, 10 s; and 72C, 20 s. The quality of the primers was
tested by analysis of the melting curve using the following
conditions: 95C, 5 s; 60C, 15 s; and 97C continuous, 1
cycle. We analyzed the expression of genes that were already
known gene targets or had been involved in hypoxia-related
signaling. The primers were designed using the Primer-Blast
online tool and oligonucleotide sequences are listed in Sup-
plementary Table S1 (Supplementary Data are available on-
line at www.liebertpub.com/scd).
Western blot analysis
Whole extracts from MSC or MSC-HIF were prepared in
ice-cold lyses buffer using M-PER Mammalian Protein Ex-
traction Reagent (Thermo Fisher Scientific; http://pierce-
net.com). Briefly, each sample was lysed in 150mL of lysis
buffer, incubated on ice at 4C for 30min, and centrifuged at
14,000 rpm for 15min (4C). Protein concentration was de-
termined using the BCA Protein Assay Kit (Thermo Fisher
Scientific). Fifty micrograms of total protein were sepa-
rated on 10% sodium dodecyl sulfate-polyacrylamide gels.
Polyvinylidene fluoride membranes were incubated with
anti-HIF-1a (BD; http://bd.com), anti-Akt (Santa Cruz Bio-
technology, Inc.; http://scbt.com), anti P-Akt Ser473 (Cell
Signaling Technology, Inc.; http://cellsignaling.com), anti-
ERK (Cell Signaling Technology, Inc.), anti P-ERK (Chemi-
con; http://chemicon.com), anti-p38MAPK (Cell Signaling
Technology, Inc.), anti P-p38MAPK (Cell Signaling Tech-
nology, Inc.), anti-NFkb (Santa Cruz Biotechnology, Inc.),
anti P-NFkb (Cell Signaling Technology, Inc.), anti-SAPK/
JNK (Cell Signaling Technology, Inc.) y anti P-SAPK/JNK
(Cell Signaling Technology, Inc.), and anti-GAPDH (Chemi-
con) antibodies. Detection was carried out using ECL Plus TM
Western blotting detection reagents Amersham (GE health-
care; http://gehealthcare.com), according to the manufac-
turer’s recommendations. Relative signal intensity was
determined by densitometry using the software Image
Quant TL (Amersham Biosciences).
Wound healing assay
Cells (MSC or MSC-HIF) were seeded in basal medium
supplemented with 10% fetal bovine serum (FBS) and were
grown to confluence onto gelatine-coated plates. The wound
was made by scraping a plastic blue tip across the monolayer.
Cells were allowed to migrate during 18h. After cell scratch-
ing, 18h later, cultures were photographed with a camera
coupled to a phase contrast microscope. Number of cells mi-
grated through the scratched area were counted in MSC-HIF
cultures and normalized versus MSC cultures. The assay was
performed in duplicated wells and repeated 3 times.
Adhesion assay
Cells were seeded in basal medium onto cover slides
previously treated with 10 mg/cm2 of fibronectin (Sigma-
Aldrich), 2 mg/cm2 of laminin (Sigma-Aldrich) and 10 mg/
cm2 of collagen (Sigma-Aldrich). After 1 h, adhered cells
were fixed with 2% paraformaldehyde (PFA), washed with
phosphate-buffered saline (PBS), labeled with 4¢,6-diamidino-
2-phenylindole (DAPI), and counted. The assay was per-
formed in triplicated wells and repeated thrice with MSC
from 2 different donors.
MSC migration assay
To study trophism induced in MSC or MSC-HIF by tro-
phic factors, cells were seeded in basal medium (Dulbecco’s
modified Eagle’s medium with 0.5% FBS) at 10,000 cells/cm2
in the top chamber of an 8mm-pore migration transwell (BD
Falcon; http://bd.com). After overnight culture, interleukin
(IL)-1b (25 ng/mL), IL-6 (25 ng/mL), IL-8 (25 ng/mL), tumor
necrosis factor (TNF-a) (20 ng/mL), hepatocyte growth fac-
tor (HGF) (25 ng/mL), serum derived factor (SDF-1a) (20 ng/
mL), or insulin growth factor (IGF) (25 ng/mL) was added to
the bottom chamber filled with basal medium and migrating
cells to the bottom side of the transwell membrane were
quantified 4 h later. FBS (10%) was used as positive controls.
Briefly, cultures were fixed with 2% PFA (Panreac Quı´mica),
the inside of the transwells were wrapped with a cotton bud
to remove nonmigrating cells, the membrane was cut and
placed in a glass slide with the bottom side upward, and
DAPI (Sigma-Aldrich) was added to stain the nuclei. The
assay was performed in duplicated wells and repeated thrice
with MSC from 3 different donors. Migrated cells were
counted and values were represented as fold increase rela-
tive to MSC passive cell migration through membranes to-
ward basal medium (untreated MSC).
Animals
Male nude rats weighing 200–250 g (HIH-Foxn1 rnu;
Charles River Laboratories, Inc.) were used. Initial number of
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animals included in the study was 70. Mortality in all groups
due to surgical procedures was about 30%.
MI and cell transplantation
Permanent ligation of the left coronary artery was per-
formed as previously described [21]. Immediately after left
descendent artery (LAD) ligation, rats were transplanted
intramyocardically (saline, 2 · 105 MSC cells or 2· 105 MSC-
HIF per animal in 3 injections of 5mL volume at 3 points of
the infarct border zone with a Hamilton syringe).
5-Ethynyl-2¢-deoxyuridine treatment
and analysis of proliferating cells
After saline or cell transplantation, a group of animals was
daily given 0.5mL i.p. injection of 5-ethynyl-2¢-deoxyuridine
(EdU) (50mg/kg b.w., i.p.) for 2 weeks. EdU labeled cells in
heart tissue were identified using an anti-EdU antibody
(Abcam). Proliferation index was calculated as a percentage
of EdU labeled nuclei per total of nuclei identified by DAPI
staining. Identification of proliferating cardiomyocytes was
performed by double staining with anti-EdU antibodies and
anti-Troponin I, respectively (Chemicon International).
About 10,000 cells were counted per animal.
Functional assessment by echocardiography
Transthoracic echocardiography was performed in rats
under inhalatory anesthesia (Sevorane) using an echocar-
diographic system (General Electrics) equipped with a 10-
MHz linear-array transducer as previously reported [21].
Measurements were taken at baseline and post-transplanta-
tion (4 weeks). Left ventricular (LV) dimensions in end di-
astole (LVDd) and end systole (LVDs), anterior and posterior
wall (AW and PW) thickness in diastole and systole, end-
diastolic area (EDA), and end-systolic area (ESA) were
measured. Fractional area change (FAC) was calculated as
[(EDA – ESA)/EDA] · 100. Fractional shortening (FS) was
calculated as [(LVDd -LVDs)/LVDd] · 100. Changes in AW
were calculated as (AWs -AWd/AWd) · 100.
Immunohistochemistry
Four weeks post-implantation, animals were euthanized,
the hearts removed, washed with PBS, and fixed in 2% PFA.
Heart tissue sections were prepared for immunohistochem-
istry as previously reported [22].
Vascular density analysis
Immunohistochemical detection of vessels was performed
with anti-rat RECA (Chemicon International). Vessels were
counted in 10 fields in the peri-infarct zone at 200 · and
referred as number of vessels per unit area (mm2) using a
light microscope and the Image Proplus 7.1 software.
Morphometry
The infarct zone in left ventricles was measured in 8–12
transverse sections of 7 mm (1 slice each 200 mm of tissue)
from apex to base fixed with 2% PFA and stained with
Masson’s trichrome. The fibrotic zone was determined by
computer planimetry (Image Proplus 7.1 software). Infarct
size was expressed as percentage of total LV area and as a
mean of all slices from each heart.
Cross-sectional cardiomyocyte area was measured in the
border infarct zone of 3 heart sections from each animal
stained with anti-laminin antibody (anti-laminin antibody;
Abcam). Myocytes with defined sarcolemmal borders were
selected for cross-sectional area measurements. Cardio-
myocytes with different sizes (0–1,100 m2) were measured in
4 animals of each group (around 1,500 cells per animal in
saline group and 3,000 cells in MSC or MSC-HIF group) as
previously described [23]. Briefly, area of cardiomyocytes
was measured by computer planimetry (Image Proplus 7.1
software) and the number of cardiomyocytes ranking from
0–100 mm, 100–200 mm, 200–300 mm, 300–400 mm, 400–
500 mm, 500–600 mm, 600–700 mm, 700–800 mm, 800–900 mm,
900–1,000 mm, and 1,000–1,100 mm were calculated in each
animal. Median and first and third quartile of small size
cardiomyocytes (0–200 mm) in each group were represented
in box- and whisker plots using the Graphpad Prism 5
software.
Number of cardiomyocytes of a given size range were
expressed as percentage of total cell count for each animal.
Distribution frequency of cardiomyocyte cross-sectional ar-
eas in saline, MSC, and MSC-HIF groups, were represented
in intervals of 100mm size with overlapping Gaussian curves
using the Graphpad Prism 5 software.
Statistical analysis
Data are expressed as mean– standard error of the mean
or median (interquartile range). Comparisons between con-
trol and experimental groups were done with the Wilcoxon
W test or the Mann–Whitney U test, as appropriate. Analyses
were conducted with SPSS and GraphPad Prism 5 software.
Differences were considered statistically significant at
P < 0.05 with a 95% confidence interval.
Results
HIF-1a overexpression induces changes in MSC
gene expression and cell signaling
MSC were transduced with lentiviral vectors either pWIPI-
GFP (named as MSC) or pWIPI-HIF-GFP (named as MSC-
HIF). After infection, 90%–95% of cultured cells were GFP
positive (Fig. 1B). HIF-1a mRNA levels were elevated
4.88–0.57-fold (Fig. 1B) and MSC-HIF cultures expressed HIF-
1a protein in normoxia (Fig. 1D).
Based on microarray analysis (article in preparation), we
investigated the upregulation of different genes in MSC-HIF.
Over 30 HIF target genes analyzed, we detected increased
expression in 11 by RT-PCR (Figs. 2A and 3A; Table 1). These
genes are implicated in angiogenesis (ANGPT1, APLN,
CD3D, CTGF, and CYR61), cell survival (BNIP3, BNIP3L,
and PIK3C3), extracellular matrix remodeling [fibroblast
growth factor 2, transforming growth factor, beta 2 (TGFb2)],
and chemotaxis (c-MET). Notably, TGFb2 was upregulated
by 7.31 – 1.25-fold, c-MET was upregulated by 3.88 – 0.22-
fold, and ANGPT1 was upregulated by 2.11 – 0.21-fold. To
investigate if non-hypoxic HIF stabilization had an impact in
PI3K/Akt and MAPK pathways immunoblot analysis was
carried out (Fig. 2B). Levels of phosphorylated Akt were
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increased (11.12 – 1.2 in MSC-HIF vs. 5.54 – 0.8 in MSC;
P < 0.05). pMAPK38 (0.87 – 0.15 in MSC-HIF vs. 0.56 – 0.1 in
MSC; P< 0.5) and pMAPKJNK (8.31 – 1.18 in MSC-HIF vs.
2.07 – 0.41 in MSC; P < 0.5) were also elevated indicating the
positive effect of HIF stabilization in MSC proliferation and
cell survival.
HIF induces expression of adhesion molecules
and promotes migration in response
to trophic signals
We next assayed the influence of HIF in MSC cell adhesion
and migration (Fig. 3). Quantitative PCR showed increase in
fold change expression of several genes implicated in cell
adhesion (AMIGO 24.8 – 0.38-fold, NCAM2 1.27 – 0.12-fold,
ITGA2 2.87 – 0.12-fold, SDC1 4.44 – 0.15-fold, and SPARC
2.03 – 10-fold) and extracellular matrix production (COLXII
3.59 – 0.69-fold; Fig. 3A). In vitro experiments showed that
HIF-1a overexpression promoted cell spreading in a wound
healing assay with 2.09 – 0.5-fold increase at 18 h (P < 0.01;
Fig. 3B). Cell adhesion to collagen (1.31 – 0.02-fold; P < 0.05)
and laminin (1.24 – 0.09-fold; P < 0.05) was also increased in
MSC-HIF versus MSC (Fig. 3C). To further investigate the
role of HIF-1a in MSC biology, cells were allowed to migrate
toward trophic factors in a transwell culture system (Fig.
3D). Migration toward IL-6 (1.93 – 0.12 in MSC-HIF vs.
1.5 – 0.18 in MSC; P < 0.05), HGF (2– 0.25 in MSC-HIF vs.
1.12 – 0.12 in MSC; P < 0.01), and SDF (1.7 – 0.23 in MSC-HIF
vs. 1.17 – 0.02 in MSC; P < 0.01) was significantly elevated.
Consistent with results shown in Fig. 3A and B, we observed
stronger changes in cytoskeletal architecture and actin reor-
ganization detected by paxillin and phaloidin stainings in
MSC-HIF versus MSC when cells were cultured under che-
motactic stimulus of SDF (Fig. 3E). These results indicate that
HIF-1a induces morphologic/structural changes in MSC that
in turn improve cell motility and response to trophism.
MSC-HIF improve cardiac function in a rat
model of MI
To test if HIF-1a expression improved therapeutic prop-
erties of MSC during cardiac repair, MSC-HIF were trans-
planted in nude rats after induction of MI. Based on our
FIG. 1. Characterization of transduced MSC cultures. (A)
pWIPI GFP and HIF-GFP lentiviral vectors. (B) Lentiviral
labeling of human MSC with pWIPI-GFP or pWIPI-HIF-GFP
yielded more than 90% of infection as detected by flow cy-
tometric analysis of GFP. (C)mRNA levels of HIF-1a in MSC
and MSC-HIF populations as assessed by qRT-PCR fold
change. (D) Expression of HIF-1a protein in MSC and MSC-
HIF. GAPDH was used as protein loading control. Data
represent the mean – SD of 3 independent experiments. MSC,
mesenchymal stem cells; HIF, hypoxia-inducible factor 1 al-
pha; GFP, green fluorescent protein; qRT-PCR, quantitative
real-time polymerase chain reaction; SD, standard deviation.
FIG. 2. Transduction of MSC with HIF-1a vectors induce
biological responses. (A) Quantification of gene transcription
levels of several HIF target genes by qRT-PCR analysis in
MSC-HIF cultures versus MSC cultures. Data are expressed
as relative fold of control (normalized values) and represent
the mean– SD of 3 independent experiments. (B) Western
blot analysis of kinase phosphorylation in MSC-HIF. Total
cell lysates (30mg) were separated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis and after blotting
incubated with specific antibodies. Anti-GAPDH was used
as loading control. Expression levels of phosphorylated
proteins were quantified by densitometry of exposed films
(*P < 0.05).
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previous observations [22] and to minimize inflammatory
infiltrates due to stem cell transplantation, cell dose was
adjusted to 200,000 cells/animal. Thus, saline solution, MSC
or MSC-HIF were transplanted into the myocardium of rats
shortly after induction of MI by LAD ligation. Four weeks
after transplantation, cardiac function parameters were
measured to assess the degree of functional recovery
achieved by the presence of MSC or MSC-HIF in the infarct
border zone. MSC-HIF group displayed a significant recov-
ery of systolic function as calculated by percentage of FAC
(33.16% – 1.51% in saline group, 38.25% – 2.03% in MSC, and
44.01% – 1.14% in MSC-HIF; P< 0.0001 in MSC-HIF vs. saline
and P < 0.05 in MSC-HIF vs. MSC in saline group) and FS
(23.23% – 0.79% in saline group, 24.96%– 1.48% in MSC and
FIG. 3. HIF-1a expression induces adhesion and migration of MSC. (A) Quantification of gene transcription levels of adhesion
molecules and extracellular matrix proteins by qRT-PCR analysis in MSC-HIF cultures versus MSC cultures. Data are expressed as
relative fold of control (normalized values) and represent themean–SD of 3 independent experiments. (B) Photomicrograph images
(200· magnification) of cell spreading assay with MSC and MSC-HIF cultures (Scale bar=100mm). Number of cells migrated
through the scratched region (delineated with black lines) were quantified. Differences were calculated after 18h of initial cell
scratching and values were normalized to MSC. (C) Adhesion of untreated MSC (black bars) and MSC-HIF (striped bars) to collagen,
fibronectin, and laminin. Data are represented as fold increase relative to MSC control (mean–SD). (D)Migration of MSC or MSC-
HIF toward trophic factors IL-1b (25ng/mL), IL-6 (25ng/mL), IL-8 (25ng/mL), TNF-a (20ng/mL), HGF (25ng/mL), SDF-1a
(20ng/mL), IGF-1 (25ng/mL), and 10% FBS (*P<0.05, **P<0.01, in different panels). (E) Double staining of MSC and MSC-HIF
cultures with phalloidin (green label) and paxilin (red label) treated with SDF-1a (25ng/mL). Nuclei were stained with DAPI (blue).
Scale bar=25mm. DAPI, 4¢,6-diamidino-2-phenylindole; IL, interleukin; TNF-a, tumor necrosis factor; HGF, hepatocyte growth
factor; SDF, serum derived factor; IGF, insulin growth factor; FBS, fetal bovine serum.
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30.15% – 0.90%, in MSC-HIF; P < 0.0001 in MSC-HIF vs.
MSC). Beneficial effects were also observed on anterior wall
thickening (AWT) at this time point (AWT: 22.64% – 0.76% in
saline group, 24.73% – 1.59% in MSC, and 26.74% – 0.92% in
MSC-HIF; P < 0.01 in MSC-HIF vs. saline; Fig. 4; Table 1).
MSC-HIF reduce fibrotic scar tissue
and induce angiogenesis
Treatment with MSC-HIF significantly reduced the area
of fibrous scar tissue (Fig. 5A); percentage of scar tissue was
29.91% – 1.72% in saline group (n = 8), 18.12% – 0.93 in MSC
group (n = 6), and 12.73% – 1.04% in MSC-HIF group (n = 11)
(P < 0.00001 in MSC-HIF vs. saline, P < 0.0001 in MSC
vs. saline, and P < 0.01 in MSC-HIF vs. MSC). Measurement
of angiogenesis at the same time point showed that
both MSC and MSC-HIF transplantation increased the
number of vessels at the peri-infarct (Fig. 5B). Number of
capillaries per mm2 was 518 – 81 in saline, 810 – 53 in
MSC, and 1,252 – 80 in MSC-HIF (P < 0.0001 in MSC-HIF
vs. saline, P < 0.01 in MSC-HIF vs. MSC and in MSC vs.
saline).
Table 1. Echocardiographic Values of Saline, Mesenchymal Stem Cells
and Mesenchymal Stem Cells-Hypoxia-Inducible Factor Groups
Saline MSC MSC-HIF
P values
(n = 13) (n = 10) (n = 11)
Saline Saline MSC
Baseline Final Baseline Final Baseline Final ANOVA vs. MSC vs. MSC-HIF vs. MSC-HIF
AWd 1.60 – 0.03 1.04 – 0.03 1.40 – 0.03 1.03 – 0.03 1.47 – 0.03 1.27 – 0.11
LVd 5.84 – 0.08 7.44 – 0.16 5.14 – 0.20 6.95 – 0.27 5.39 – 0.19 7.03 – 0.17
PWd 1.46 – 0.05 1.58 – 0.08 1.44 – 0.04 1.38 – 0.11 1.44 – 0.09 1.58 – 0.08
AWs 2.44 – 0.05 1.35 – 0.04 2.31 – 0.12 1.37 – 0.05 2.37 – 0.07 1.77 – 0.16
LVs 3.43 – 0.05 5.68 – 0.16 2.92 – 0.11 5.21 – 0.20 3.15 – 0.14 4.91 – 0.14 0.003
PWs 2.13 – 0.09 2.08 – 0.12 2.04 – 0.08 1.97 – 0.09 2.09 – 0.07 2.14 – 0.07
EDA 31.41 – 0.64 44.38– 1.55 27.29 – 1.39 44.12 – 2.10 25.91– 1.23 41.73– 1.69
ESA 8.66 – 0.40 29.67– 1.36 7.64 – 0.47 27.36 – 1.85 7.61 – 0.49 22.93– 1.41 0.002
FS 41.23 – 0.70 23.23– 0.79 43.23– 1.00 24.96 – 1.48 41.72– 0.96 30.15– 0.90 0.0007 0.03
FAC 72.42 – 1.11 33.16– 1.51 71.86– 1.57 38.25 – 2.03 70.53– 1.02 44.01– 1.14 0.02 0.0001 0.01
AWT 34.49 – 0.85 22.64– 0.76 38.95– 1.75 24.73 – 1.59 37.75– 0.70 26.74– 0.92 0.008
All values are mean– SEM. AWd, LVd, PWd, AWs, LVs, and PWs are expressed in mm, whereas EDA and ESA are expressed in mm2. FS,
FAC, and AWT are expressed as percentage.
MSC, mesenchymal stem cells; HIF, hypoxia-inducible factor; ANOVA, analysis of variance; AWd, anterior wall diastole thickness; AWs,
anterior wall systole thickness; AWT, anterior wall thickening; EDA, end-diastolic area; ESA, end-systolic area; FAC, fractional area change;
FS, fractional shortening; LVd, left ventricular diastole internal dimension; LVs, left ventricular systole internal dimension; MI, myocardial
infarction; PWd, posterior wall diastole thickness; PWs, posterior wall systole thickness; SEM, standard error of the mean.
FIG. 4. Improvement of LV
function in MSC-HIF-treated
animals. (A) Representative
echocardiographic images of 1
animal from saline (n= 13),
MSC (n=10) and MSC-HIF
(n=11) groups. Quantified
values of area fractional change
(FAC). (B) Representative 2-
dimensional systolic frame
showing differences in wall
motion. Quantified values of
fractional shortening (FS) and
anterior wall thickness (AWT)
are given. Data are expressed
as mean–SEM. (*P<0.05,
**P<0.01, ***P<0.001 in both
panels). LV, left ventricular;
SEM, standard error of the
mean.
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MSC-HIF treatment promotes myocardial
tissue regeneration
Next, we analyzed the number of proliferating cells in the
border zone of EdU-treated animals (n=6 in each group). After
2 weeks, animals treated daily with EdU were sacrificed and
the infarcted area was subjected to histological studies. At the
doses analyzed, we did not detect engrafted cells in cell-treated
animals. However, cell transplantation increased proliferation
in heart tissue (Fig. 6A). Proliferation Index was
17.81%–2.86% in saline, 26.82%–3.05% in MSC, and
22.44%–1.22% in MSC-HIF; P< 0.05 in MSC and MSC-HIF vs.
saline). Double staining Edu/Troponin I revealed the presence
of proliferating cardiomyocytes. Cardiomyocyte proliferation
index was 2.32%– 0.34% in saline group (n=5), 2.86%–0.18%
in MSC group (n=6), and 4.39%–0.61% in MSC-HIF group
(n=5); (P< 0.05 in MSC vs. saline and P<0.01 in MSC-HIF vs.
saline). These results point to a paracrine effect as a mechanism
induced by cell transplantation.
Finally, we wanted to evaluate if cardiac hypertrophy
contributed to the increase in myocardial tissue in animals
transplanted with MSC or MSC-HIF. For this purpose, car-
diomyocyte area in the border zone of the infarct was cal-
culated from heart sections stained with anti-laminin and
anti-troponin I antibodies (Fig. 6B). Small size cardiomyo-
cytes (less than 200mm2) were more abundant in cell-treated
animals (16.21 – 2.47 in saline, 24.34– 7.28 in MSC, and
27.13– 4.45 in MSC-HIF; P < 0.05 in MSC-HIF vs. saline) (Fig.
6C). However, when analyzing cardiomyocyte global sizes,
we observed that relative to saline-treated animals, in both
MSC and MSC-HIF groups the distribution of myocyte cross-
sectional area was shifted to the left with no significant dif-
ferences in cardiomyocyte area, indicating the absence of
cardiac hyperthrophy.
Discussion
HIF-1a plays different roles in cardiac tissue that have
been extensively studied [7]. While accumulation of HIF-1a
in cardiomyocytes lead to reduced contractility in the adult
and deterioration of ventricular function [24,25], over-
expression of these transcription factor attenuated cardiac
dysfunction following MI probably due to an increase in
blood perfusion and glycolysis and reduction of apoptosis
[12,13,26]. In this context, stabilization of HIF-1a in inducible
polylhydroxylases (PHD) knockout mice (Phd2flox/flox mice)
lead to an HIF-dependent tissue protection in case of MI,
with increased capillary density and preserved cardiac
structure and function [27]. The authors reported that the
success of the approach was to avoid HIF stabilization dur-
ing heart development, preventing the activation of detri-
mental pathways, while modulating the expression of PHD2
in the adult. Considering the dangerous potential of HIF-1a
stabilization in cardiac tissue, we wanted to potentiate HIF-
induced therapeutic mechanisms, without modulation of
HIF levels within the heart, using cell therapy.
MSC are an attractive approach to repair ischemic tissues
and hypoxia is considered an important stimulus to poten-
tiate their therapeutic mechanisms [28]. In a previous study,
we reported that MSC reduced scar tissue formation and
increased neovascularization more efficiently than other
adult stem cell types [22]. The MSC-dependent paracrine
mechanisms observed in vivo seemed to be triggered by
hypoxia, since cells injected in the viable myocardium at the
border zone often migrated to the ischemic fibrotic tissue,
indicating not only a homing to the site of injury but also the
ability of these cells to survive in hypoxic environments.
Indeed, physiological niches of bone marrow stem cells dis-
play reduced oxygen levels and this condition is essential to
maintain their self-renewal capacity and pluripotency [29].
Following this rationale, we wanted to investigate the ef-
fect of a constitutive form of HIF-1a in MSC biology and
therapeutics. This new strategy could be important to: (1)
manipulate MSC in normoxia to mimic some of the effects
induced by hypoxia, (2) identify the mechanisms by which
MSC increase their survival and paracrine effects, and (3)
FIG. 5. Effect of MSC-HIF transplantation on infarct size
and angiogenesis. (A) Representative heart sections from
infarcted nude rats receiving saline (n = 8), MSC (n= 6), or
MSC-HIF (n = 11). Fibrotic area (blue color) in the LV was
calculated in Masson’s Trichrome-stained sections. Animals
were euthanized 4 weeks post-transplantation. Values are
the mean– SEM. (B) Representative sections of saline, MSC,
and MSC-HIF-treated animals (n = 9 in each group) stained
with anti-RECA (red), and quantification of the total number
of vessels in different groups (lined in white) using an image
analyzer software. Scale bar = 200mm. (**P < 0.01, ***P < 0.001,
****P < 0.0001 in both panels).
HIF-1a-ENGINEERED MSC FOR MYOCARDIAL REPAIR 507
determine HIF target molecules in MSC that could contribute
to hypoxia-induced MSC phenotype.
MSC-HIF were analyzed by western blot and RT-PCR to
determine HIF-1a expression levels at mRNA and protein
level. Analysis of the main signaling pathways activated in
MSC-HIF revealed that HIF-1a accumulation activated
PI3K/Akt. These results are consistent with previous reports
showing that HIF stabilization promotes AKT phosphoryla-
tion in MSC [18]. Moreover, it has been suggested that PI3K/
Akt are linked to the phosphorylation of the MAPK and
SAPK/JNK pathways in MSC and other cell types, which
could explain the increase in phosphorylation of p38MAPK
FIG. 6. MSC-HIF-treated animal showed increase in cardiomyocyte proliferation with no hypertrophy of heart tissue. (A)
Confocal image of double staining with anti-Tn I (red) and anti-EdU (green) antibodies of a heart section from an MSC-HIF-
treated animal (arrow points show double labeled proliferating cardiomyocytes). Nuclei are labeled with DAPI (blue). Scale
bar = 30 mm (image at 400 ·magnification). Proliferation index (number of EdU+cells/total nuclei) · 100 and cardiomyocyte
proliferation index (EdU +TnI+ cells/total TnI +DAPI + ) · 100 are indicated as a percentage. (*P < 0.05, **P < 0.01). (B) Re-
presentative fluorescent image of a heart section double stained with anti-laminin (green) and anti-troponin I (red) antibodies
(200 · magnification). Myocyte regions at the border zone were selected for analysis of cross-sectional area. (C) Box plots
showing cross-sectional area of small cardiomyocytes (0–200 mm) detected in saline, MSC, and MSC-HIF groups. Boxes show
the median and the 25th and 75th percentile. P < 0.05 in MSC-HIF versus saline. (D) Distribution frequency of myocyte cross-
sectional areas at the border zone in saline (n = 4), MSC (n= 4), and MSC-HIF (n = 5) groups. Around 3,000 cardiomyocytes
were analyzed per animal. Mean of cardiomyocytes ranking from 0 to 1,200mm2 with intervals of 100 mm are indicated and
represented with Gaussian curves. (E) Merge of Gaussian curves representing cardimyocyte distribution size corresponding
to saline (black line), MSC (blue line), and MSC-HIF (red line) groups. No significant differences were observed among groups
indicating the absence of cardiac hypertrophy in cell-treated groups. EdU, 5-ethynyl-2¢-deoxyuridine
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and SAPK/JNK kinases in MSC-HIF. Since constitutive ex-
pression of HIF-1a induced Akt and SAP/JNK phosphory-
lation in MSC-HIF (Fig. 2) we hypothesize a possible
autocrine loop among these molecules in MSC. Other
mechanisms like downregulation of E2A-p21 by HIF-TWIST
axes has also been reported to preserve MSC self-renewal
capacity and to reduce senescence [28].
We next investigated the impact of HIF-1a on MSC gene
expression. Gain-of-function studies in MSC showed that
HIF-1a coordinately regulated the expression of genes
encoding proteins and growth factors implicated in wound
repair, angiogenesis, and extracellular matrix production,
most of them previously described as HIF targets [30–35].
Proangiogenic factors including angiopoietin (ANGPT1),
apelin (APLN), and the matricellular protein CYR61
(CNN1) were upregulated in MSC-HIF. Expression of
ANGPT1 and APLN1 is modulated by hypoxia and HIF-1a
in cardiac myocytes and both promote beneficial effects on
cardiac function and blood pressure [32,34]. Similarly, the
proangiogenic factor CYR61 (CNN1) has been implicated
in fibroblast senescence as a mechanism for controlling
fibrogenesis in wound healing [36]. Strikingly, we do not
observe upregulation of VEGF mRNA levels in MSC-HIF.
Similar results were observed at the protein level in a cy-
tokine assay of MSC-HIF/MSC culture supernatants (not
shown). A possible explanation is that MSC express high
levels of VEGF in normoxia that make difficult the detec-
tion of changes in VEGF levels between MSC-HIF and
MSC.
TGFb and connective tissue factor (CTGF) are also HIF
target genes. Several studies suggested that TGFb may be
crucial for stem cell-based myocardial repair by repression of
inflammatory gene synthesis mediating resolution of the
inflammatory infiltrate [37,38]. In addition, TGFb increases
cell adhesion and regulates matrix metalloproteinases re-
quired for MSC migration through extracellular matrix bar-
riers [39]. In this context, CTGF is a downstream mediator of
both TGFb signaling [40] and G-coupled protein receptor 30
(GPER), and recently its activation in HL-1 cardiomyocytes
have been linked to stabilization of HIF-1a and associated to
anti-apoptotic mechanisms [41,42].
In addition, expression of integrins and genes related to
connective tissue synthesis, and cytosqueleton reorganiza-
tion were upregulated in MSC-HIF, that in turn improved
wound healing and MSC locomotory behavior in functional
studies of chemotaxis (Fig. 3).
BNIP3/BNIP3L are 2 HIF targets genes that also were
upregulated in MSC-HIF. The activation of these molecules
may seem contradictory with the rest of survival signals
triggered by HIF-1a overexpression, since they belong to the
intrinsic mitochondria-linked death pathway. However, the
alternative splicing of BNIP3 in ventricular myocytes during
hypoxia has been recently described as a novel defense
mechanism [43]. Thus, a similar mechanism cannot be dis-
carded in MSC-HIF.
Of particular relevance was the increased migration to-
ward SFD and HGF. These 2 molecules are implicated in the
CXCR4 and c-Met axis respectively, that not only are acti-
vated in response to hypoxia, but also mediate the migration
and homing of bone marrow-derived cells in vivo [29,44–46].
All these biological processes could be responsible for an
improved MSC-mediated cardiac healing.
Thus, the major findings of this study are: (1) HIF-1a
triggers activation of PI3K/Akt, p38MAPK, and MAPK/JNK
signaling pathways, (2) HIF-1a overexpression increases cell
adhesion and induces structural changes and cytoskeleton
reorganization, (3) HIF-1a increases cellular responses to
trophics factors in vivo and in vitro, (4) MSC-HIF showed
increased ability to repair cardiac function in an experi-
mental model of MI, in correlation with increased ability to
induce angiogenesis and decrease tissue fibrosis, and (5)
Intracardiac injection of MSC-HIF induced cardiomyocyte
proliferation in the absence of cardiac hyperthrophy.
These results are in accordance with previous studies in
models of calvarial defects showing that treatment with MSC
overexpressing HIF-1a promote angiogenesis and osteogen-
esis [20]. These kinds of approaches, together with others
based on direct stabilization of HIF-1a in ischemic tissues,
has led to phase I and II clinical studies in patients with
severe pheripheral arterial disease [47].
Only 2 PHD inhibitors, FG-2216 and FG-4592, have pro-
gressed to clinical setting (http://clinicaltrials.gov/identifiers
NCT00456053, NCT00761657), but it is conceivable that other
drugs will be discovered and approved soon. In this context,
the stabilization of HIF-1a in MSC-HIF cultures could be
useful for the screening of new drugs aiming to modulate
HIF activity.
A limitation of our approach is that we have examined the
action of HIF-1a in normoxia in vitro, so we cannot discard
additional mechanisms in hypoxic culture. However, the
observed in vivo effects are likely to be more accurate and to
recapitulate the effects of HIF-1a in hypoxic environments
resulting from cardiac ischemia.
Overall, this study demonstrates that HIF-1a expression in
MSC potentiates therapeutic mechanisms and adds new in-
formation about the repair processes induced by MSC.
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